Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularisation due to age-related macular degeneration

PurposeAlthough visual acuity is the most frequently used primary outcome measure in clinical trials of treatments for choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD), contrast sensitivity may provide valuable additional information. This paper reviews the evidence for using contrast sensitivity as a measure of visual function and as an outcome measure in clinical trials in patients with subfoveal CNV due to AMD.MethodsMedline database searches were performed to retrieve relevant articles on contrast sensitivity. In addition, articles were included from the authors' knowledge of the literature and from the reference lists of retrieved articles.ResultsThe published literature demonstrates that contrast sensitivity is an important measure of visual function in patients with subfoveal CNV due to AMD. Most clinical trials of treatments for CNV due to AMD have reported visual acuity as the primary outcome. However, there is evidence that treatment (such as verteporfin therapy) may also provide additional benefits in terms of contrast sensitivity. These benefits may not be completely characterised by measurement of visual acuity alone.ConclusionsThe inclusion of contrast sensitivity as an outcome measure in studies of patients with CNV due to AMD may provide a more complete understanding of the effects of treatment on visual function and the likely benefits for patients.

[1]  G S Rubin,et al.  A comprehensive assessment of visual impairment in a population of older Americans. The SEE Study. Salisbury Eye Evaluation Project. , 1997, Investigative ophthalmology & visual science.

[2]  G McGwin,et al.  Visual risk factors for driving difficulty among older drivers. , 2000, Accident; analysis and prevention.

[3]  Beth T. Stalvey,et al.  Timed Instrumental Activities of Daily Living Tasks: Relationship to Visual Function in Older Adults , 2001, Optometry and vision science : official publication of the American Academy of Optometry.

[4]  A. Bird,et al.  Visual outcomes in the subfoveal radiotherapy study: a randomized controlled trial of teletherapy for age-related macular degeneration. , 2002, Archives of ophthalmology.

[5]  M. Schneck,et al.  The Relation Between Visual Acuity and Other Spatial Vision Measures , 2000, Optometry and vision science : official publication of the American Academy of Optometry.

[6]  R. Cumming,et al.  Visual Impairment and Falls in Older Adults: The Blue Mountains Eye Study , 1998, Journal of the American Geriatrics Society.

[7]  T. Kuyk,et al.  Visual factors and mobility in persons with age-related macular degeneration. , 1999, Journal of rehabilitation research and development.

[8]  M. Bullimore,et al.  Improving the Reliability of the Pelli-Robson Contrast Sensitivity Test , 1991, Noninvasive Assessment of the Visual System.

[9]  L. Fried,et al.  Visual Impairment and Disability in Older Adults , 1994, Optometry and vision science : official publication of the American Academy of Optometry.

[10]  G E Legge,et al.  Psychophysics of reading. Clinical predictors of low-vision reading speed. , 1992, Investigative ophthalmology & visual science.

[11]  Denis G. Pelli,et al.  THE DESIGN OF A NEW LETTER CHART FOR MEASURING CONTRAST SENSITIVITY , 1988 .

[12]  JAN E. LOVIE-KITCHIN,et al.  Vision and Mobility Performance of Subjects with Age-Related Macular Degeneration , 2002, Optometry and vision science : official publication of the American Academy of Optometry.

[13]  DIFFERENCE BETWEEN OPHTHALMOLOGISTS' AND PATIENTS' PERCEPTIONS OF QUALITY OF LIFE ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION , 2000 .

[14]  David B Elliott,et al.  Comparing clinical tests of visual function in cataract with the patient's perceived visual disability , 1990, Eye.

[15]  S. Gandolfi,et al.  Self-assessment of the quality of vision: association of questionnaire score with objective clinical tests. , 1998, Current eye research.

[16]  Verteporfin Roundtable Participants.  GUIDELINES FOR USING VERTEPORFIN (VISUDYNE®) IN PHOTODYNAMIC THERAPY TO TREAT CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSES , 2002, Retina.

[17]  R. Klein,et al.  The Beaver Dam Eye Study. Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus. , 1992, Ophthalmology.

[18]  D. Wu,et al.  The contrast sensitivity function in low vision. , 1992, Yan ke xue bao = Eye science.

[19]  Michael Stur,et al.  Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. , 2003, American journal of ophthalmology.

[20]  G. Breart,et al.  Fall-related factors and risk of hip fracture: the EPIDOS prospective study , 1996, The Lancet.

[21]  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. , 2001 .

[22]  R. Cumming,et al.  Visual function tests, eye disease and symptoms of visual disability: a population‐based assessment , 2000, Clinical & experimental ophthalmology.

[23]  I. Bailey,et al.  Visual Factors and Orientation‐Mobility Performance , 1982, American journal of optometry and physiological optics.

[24]  P. Mitchell,et al.  Causes of visual impairment in two older population cross-sections: The Blue Mountains Eye Study , 2003, Ophthalmic epidemiology.

[25]  J. Brabyn,et al.  Reading Performance in Older Adults with Good Acuity , 2001, Optometry and vision science : official publication of the American Academy of Optometry.

[26]  G B Arden,et al.  The importance of measuring contrast sensitivity in cases of visual disturbance. , 1978, The British journal of ophthalmology.

[27]  N. Bressler.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. , 2002, American journal of ophthalmology.

[28]  A. Deutman,et al.  A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation , 1998, Graefe's Archive for Clinical and Experimental Ophthalmology.

[29]  G S Rubin,et al.  The association of multiple visual impairments with self-reported visual disability: SEE project. , 2001, Investigative ophthalmology & visual science.

[30]  J. Rovamo,et al.  CONTRAST SENSITIVITY IN EVALUATION OF VISUAL IMPAIRMENT DUE TO MACULAR DEGENERATION AND OPTIC NERVE LESIONS , 1983, Acta ophthalmologica.

[31]  B. Cole,et al.  Assessment of contrast sensitivity of patients with macular disease using reduced contrast near visual acuity charts , 1988, Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians.

[32]  R. Guymer,et al.  New treatments in age‐related macular degeneration , 2003, Clinical & experimental ophthalmology.

[33]  G. Brown,et al.  Utility values and age-related macular degeneration. , 2000, Archives of ophthalmology.

[34]  G. Rubin,et al.  Visual acuity and contrast sensitivity in patients with neovascular age-related macular degeneration. Results from the Radiation Therapy for Age-Related Macular Degeneration (RAD-) Study. , 2003, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie.

[35]  N. Bressler,et al.  Are the submacular surgery trials still relevant in an era of photodynamic therapy? , 2001, Ophthalmology.

[36]  R. Klein,et al.  Performance-based and self-assessed measures of visual function as related to history of falls, hip fractures, and measured gait time. The Beaver Dam Eye Study. , 1998, Ophthalmology.

[37]  S. Cummings,et al.  Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. , 1995, The New England journal of medicine.

[38]  T. Olsen.  Submacular Surgery for Age-Related Macular Degeneration , 1997 .

[39]  G. Rubin.  RELIABILITY AND SENSITIVITY OF CLINICAL CONTRAST SENSITIVITY TESTS , 1988 .

[40]  A. Tarkkanen,et al.  Visual function after strontium-90 plaque irradiation in patients with age-related subfoveal choroidal neovascularization. , 1999, Acta ophthalmologica.

[41]  C. Owsley,et al.  Contrast sensitivity, acuity, and the perception of 'real-world' targets. , 1987, The British journal of ophthalmology.

[42]  U Chakravarthy,et al.  Relation between macular morphology and visual function in patients with choroidal neovascularisation of age related macular degeneration , 2001, The British journal of ophthalmology.

[43]  J. Alexander,et al.  Radiotherapy for recurrent choroidal neovascularisation complicating age related macular degeneration , 2003, The British journal of ophthalmology.

[44]  Ronald Klein,et al.  Associations of visual function with physical outcomes and limitations 5 years later in an older population: the Beaver Dam eye study. , 2003, Ophthalmology.

[45]  N. Bressler,et al.  EFFECTS OF VERTEPORFIN THERAPY ON CONTRAST SENSITIVITY: Results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Investigation—TAP Report No. 4 , 2002, Retina.

[46]  S J Leat,et al.  Reading performance with low vision aids: relationship with contrast sensitivity , 1993, Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians.

[47]  D. Archer,et al.  Treatment of age-related subfoveal neovascular membranes by teletherapy: a pilot study. , 1993, The British journal of ophthalmology.

[48]  N. Bressler.  Submacular surgery. New information, more questions. , 1997, Archives of ophthalmology.

[49]  J. Alexander,et al.  External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double-masked, randomized clinical trial. , 2001, Archives of ophthalmology.

[50]  J W Berger,et al.  Age-related macular degeneration. , 2000, The New England journal of medicine.

[51]  G. Brown,et al.  Vision and quality-of-life. , 1999, Transactions of the American Ophthalmological Society.

[52]  R. Sekuler,et al.  Aging and low-contrast vision: face perception. , 1981, Investigative ophthalmology & visual science.

[53]  P. Artes,et al.  Face recognition in age related macular degeneration: perceived disability, measured disability, and performance with a bioptic device , 2002, The British journal of ophthalmology.

[54]  J. Wood,et al.  Age and Visual Impairment Decrease Driving Performance as Measured on a Closed-Road Circuit , 2002, Hum. Factors.

[55]  William J Feuer,et al.  Impact of visual function on computer task accuracy and reaction time in a cohort of patients with age-related macular degeneration. , 2002, American journal of ophthalmology.

[56]  Gordon E Legge,et al.  Psychophysics of reading XX. Linking letter recognition to reading speed in central and peripheral vision , 2001, Vision Research.

[57]  M G Maguire,et al.  Assessment of visual function in patients with age-related macular degeneration and low visual acuity. , 1988, Archives of ophthalmology.

[58]  U. Chakravarthy,et al.  Questionnaire-based survey on the importance of quality of life measures in ophthalmic practice , 1998, Eye.